Ann: First Patient Dosed in MND Phase 1/2 Trial, page-156

Hi Enkayess,

Great post. In relation to AMX 0035.

According to Ref ( MNDA AMX0035 What does the drug do ? )

The drug increases life expectancy by 6.5 months.

The drug has a relatively small slowing of disease symptoms.

The study " Effects of investigational
drug Sodium Phenylbutyrate(AMX005) on the transcriptional and metabolic landscape of sporadic ALS Fibrolasts . Fels et al. 2022

Comments via the diagrams that autophagic events are present but minimal in the scheme of what we know of the mTOR pathway required to fulfil clearance of misfolded proteins.

Another problem the patent holders have to over come is " early gastrointestinal adverse events are normal "

I am not predicting the future of the current phase 3 just trying to supply objective comment with references..